Article By:
Cullen Roche
Friday, September 22, 2023 4:35 PM EDT
T-Bills are an incredibly attractive option at this time. At 5.5% you’re getting high income, high principal stability, and tax efficiency across very predictable short-term time horizons.
Read
Article By:
Alex Demolitor
Friday, September 22, 2023 3:57 PM EDT
With the fundamental roadblocks adding up, silver confronts a bearish outlook at nearly every turn.
In this article: OIL, SLV
Read
Article By:
Dividends4Life
Friday, September 22, 2023 3:10 PM EDT
Realty Income Corporation is an equity real estate investment trust that owns, develops, and manages retail real estate, primarily single-tenant buildings throughout most of the U.S.
In this article: O
Read
Article By:
Interactive Brokers
Friday, September 22, 2023 2:57 PM EDT
This morning’s weak PMI data reflecting slower economic growth in the United States and recessionary conditions in the Eurozone are subduing bond yields with investors buying the dips in securities.
Read
Article By:
Przemyslaw Radomski, CFA
Friday, September 22, 2023 2:45 PM EDT
Gold was not the only part of the precious metals sector that reversed in a profound manner. We saw the same things in silver and mining stocks.
In this article: GDX, GLD, SLV
Read
Article By:
Chris Kimble
Friday, September 22, 2023 2:33 PM EDT
A look at the performance of one of the largest and most popular bullish (long) treasury bond ETFs, the 20+ year ETF vs. its counterpart, the bearish (short) 20+ year treasury bond ETF.
In this article: TBF, TLT
Read
Market volatility has been remarkably low in 2023, apart from the brief shock following the failure of Silicon Valley Bank earlier this year.
The longer inflation stays higher, the more power unions have. And the more power unions have, the more momentum inflation has.
A reasonable backdrop between the summer selloff, sentiment, positioning, and buybacks suggests a push higher by year-end.
Over the past year, UBS’s share price rose about 59% from $16.14 to $25.66 as of Thursday’s market close.
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
This article examines 15 such stocks that are heavily involved in the research and development of qubits..
One of the large homebuilding companies in the United States has seen its shares fall over 15% in a few weeks and is now trading below book value. Our team sees this as an opportunity to get long.
